Antimicrobial agent-55

Antimicrobial agent-55 exhibits potent broad-spectrum antimicrobial activity, with an MIC₅₀ of 0.27 μM against E. coli ATCC 8739, and shows activity against MRSA (MIC₅₀ ≤10 μM)^[1].
Antimicrobial agent-55 induces topoisomerase-inhibiting phenotypes in Bacillus subtilis 2020, including cell elongation, nucleoid condensation, abnormal FtsZ ring localization, and membrane foci^[1].
Antimicrobial agent-55 activates the SOS DNA damage response in Bacillus subtilis UG10, which is evidenced by the formation of RecA aggregates^[1].
Antimicrobial agent-55 inhibits E. coli DNA gyrase, S. aureus topoisomerase IV, and LpxC, with IC₅₀ values of 0.315, 1.553, and 0.108 μM, respectively^[1].
Antimicrobial agent-55 (20 days) exhibits extremely low potential for the development of bacterial resistance in Staphylococcus aureus, with only a slight 2- to 3-fold increase in MIC observed within 20 days^[1].
The IC₅₀ values of cytotoxicity of Antimicrobial agent-55 against SH-SY5Y and WI-38 cells are 68.15 μM and 80.03 μM, respectively, with a bacterial selectivity index of 25^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.